首页> 外文期刊>Journal of Pharmaceutical Analysis >Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants
【24h】

Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants

机译:SARS-CoV-2 3CL pro 和药用植物抗 COVID-19 药物发现的结构基础

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The recent pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has raised global health concerns. The viral 3-chymotrypsin-like cysteine protease (3CLpro) enzyme controls coronavirus replication and is essential for its life cycle. 3CLpro is a proven drug discovery target in the case of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Recent studies revealed that the genome sequence of SARS-CoV-2 is very similar to that of SARS-CoV. Therefore, herein, we analysed the 3CLpro sequence, constructed its 3D homology model, and screened it against a medicinal plant library containing 32,297 potential anti-viral phytochemicals/traditional Chinese medicinal compounds. Our analyses revealed that the top nine hits might serve as potential anti- SARS-CoV-2 lead molecules for further optimisation and drug development process to combat COVID-19.Graphical abstractDownload : Download high-res image (236KB)Download : Download full-size image
机译:最近由 SARS-CoV-2 引起的 2019 冠状病毒病 (COVID-19) 大流行引发了全球健康问题。病毒 3-糜蛋白酶样半胱氨酸蛋白酶 (3CLpro) 控制冠状病毒复制,对其生命周期至关重要。3CLpro是治疗严重急性呼吸系统综合症冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)的成熟药物发现靶点。最近的研究表明,SARS-CoV-2的基因组序列与SARS-CoV的基因组序列非常相似。因此,本文分析了3CLpro序列,构建了其3D同源模型,并将其与包含32,297种潜在抗病毒植物化学物质/中药化合物的药用植物库进行了筛选。我们的分析显示,前九名热门药物可能作为潜在的抗 SARS-CoV-2 先导分子,用于进一步优化和药物开发过程以对抗 COVID-19。图形抽象下载 : 下载高分辨率图片 (236KB)下载 : 下载全尺寸图片

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号